<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363705">
  <stage>Registered</stage>
  <submitdate>14/02/2013</submitdate>
  <approvaldate>19/02/2013</approvaldate>
  <actrnumber>ACTRN12613000197730</actrnumber>
  <trial_identification>
    <studytitle>Study of the pharmacokinetics [the way the body handles drug] of paracetamol and phenylephrine in healthy adults
</studytitle>
    <scientifictitle>Randomised single dose two arm cross-over open label study to determine the bioavailability of paracetamol and phenylephrine tablets relative to concomitant administration of Sudafed Nasal Decongestant and Panadol after an oral administration of two tablets to healthy adults under fasting conditions</scientifictitle>
    <utrn />
    <trialacronym>AFT MXPE02</trialacronym>
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cold and Flu</healthcondition>
    <conditioncode>
      <conditioncode1>Other</conditioncode1>
      <conditioncode2>Research that is not of generic health relevance and not applicable to specific health categories listed above</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Drug and dose: Paracetamol 1000mg and Phenylephrine 10mg
Dose frequency: single dose
Duration Administration: single dose
Mode Administration: Oral tablet
Wash-out between treatments = 7 days</interventions>
    <comparator>Paracetamol 1000mg; Phenylephrine HCL 10mg
Frequency - single dose
Duration - single dose
Mode administration - oral tablet</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Evaluation of Pharmacokinetic paramaters [Cmax, AUC, Tmax, T 1/2] of Phenylephrine hydrochloride
Assessed by measurement of plasma drug concentrations</outcome>
      <timepoint>Single dose study measuring plasma concentrations over 5, 15, 30, 45 minutes and 1, 1.25, 1.5, 2, 3, 6, 8, 10 and 12 hours after study drug administration.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety will be evaluated during each study period, and for 7 days following study drug administration. 
An acute safety evaluation will be performed during each study period by recording spontaneously reported adverse events and by clinical assessments, including measurements of blood pressure and heart rate.
 
Known phenylephrine hydrochloride adverse effects (i.e increased systolic and diastolic blood pressure, palpitations, headache, vomiting, nervousness), and known paracetamol adverse effects (i.e. clinical evidence of hepatotoxicity) will be compared between groups.
Adverse events will continue to be assessed up to 7 days after the last dose of the study medication by spontaneous reporting and at a final follow-up phone call.
</outcome>
      <timepoint>Single dose study measuring plasma concentrations over 5, 15, 30, 45 minutes and 1, 1.25, 1.5, 2, 3, 6, 8, 10 and 12 hours after study drug administration.
Primary outcome is derived from the plasma-time AUC values over this entire time period</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Healthy volunteers</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>40</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>pregnancy, nursing, drug abuse, smoking &gt; 10 cigarettes per day, excess alcohol intake, Rx drugs within 14 days of the study, participating in another trial within 80 days, clinically significant abnormal lab tests</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Pharmacokinetics</endpoint>
    <statisticalmethods>90% confidence intervals for the mean ratios calculated using the residual variance from an ANOVA of log transformed values. 
The ANOVA model will include terms for participant, period and formulation.</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate>4/03/2013</anticipatedstartdate>
    <actualstartdate>3/03/2013</actualstartdate>
    <anticipatedenddate>12/03/2013</anticipatedenddate>
    <actualenddate>12/03/2013</actualenddate>
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Jordan</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>AFT Pharma</primarysponsorname>
    <primarysponsoraddress>Level 1, 129 Hurstmere Rd, Takapuna 0622</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>AFT Pharma</fundingname>
      <fundingaddress>Level 1, 129 Hurstmere Rd, Takapuna, Auckland, 0622</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To measure the pharmacokinetics [how the body treats drugs] of phenylephrine in humans since this is still not well understood</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>IPRC Institutional Review Board</ethicname>
      <ethicaddress>172 Queen Rania St
PO Box 963166
Amman 11942</ethicaddress>
      <ethicapprovaldate>24/02/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>11/02/2013</ethicsubmitdate>
      <ethiccountry>Jordan</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>Abdullah Hiyari</name>
      <address>International Pharmaceutical Research Center
Queen Rania St - Sport City Circle
PO Box 963166
Amman 11196</address>
      <phone>+962562764/51</phone>
      <fax>+96265627654</fax>
      <email>iprc@iprc.com.jo</email>
      <country>Jordan</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Isam Salem</name>
      <address>International Pharmaceutical Research Center
Queen Rania St - Sport City Circle
PO Box 963166
Amman 11196</address>
      <phone>+962562764/51</phone>
      <fax>+96265627654</fax>
      <email>dr.salem@iprc.com.jo</email>
      <country>Jordan</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Hartley Atkinson</name>
      <address>Level 1, 129 Hurstmere Rd, Takapuna, Auckland 0622</address>
      <phone>+6494880232</phone>
      <fax />
      <email>hartley@aftpharm.com</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>